

HBM BIOVENTURES CAYMAN LTD  
Form SC 13G  
February 16, 2012

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549**

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934  
(Amendment No.    )\***

**ChemoCentryx, Inc.**

(Name of Issuer)

**Common Stock**

(Title of Class of Securities)

**16383L106**

(CUSIP Number)

**February 13, 2012**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
- ☐ Rule 13d-1(c)
- ☒ Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 16383L106

- |  |   |  |
|--|---|--|
| 1.   | Names of Reporting Persons<br>HBM BioVentures (Cayman) Ltd.   |  |
| 2.   | Check the Appropriate Box if a Member of a Group (See Instructions)                                       |  |
|  | (a)   | <input type="radio"/>                  |
|  | (b)   | <input type="radio"/>                  |
| 3.   | SEC Use Only  |  |
| 4.   | Citizenship or Place of Organization<br>Cayman Islands, British West Indies                               |  |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With: | 5.  | Sole Voting Power<br>2,637,301(1)      |
|  | 6.  | Shared Voting Power<br>0               |
|  | 7.  | Sole Dispositive Power<br>2,637,301(1) |
|  | 8.  | Shared Dispositive Power<br>0          |
| 9.   | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2,637,301(1)                              |  |
| 10.  | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="radio"/> |  |
| 11.  | Percent of Class Represented by Amount in Row 9<br>7.9%(2)  |  |
| 12.  | Type of Reporting Person (See Instructions)<br>CO   |  |

---

(1) The Board of Directors of HBM BioVentures (Cayman) Ltd. has sole voting and investment power with respect to the shares held by such entity and acts by majority vote. The board of directors of HBM BioVentures (Cayman) Ltd. is comprised of John Arnold, Sophia Harris, Richard Coles, Dr. Andreas Wicki and John Urquhart, none of whom has individual voting or investment power with respect to the shares.

(2) This percentage is calculated based upon 33,218,325 shares of the Issuer's Common Stock outstanding as of February 8, 2012, as set forth in Issuer's final prospectus dated February 8, 2010, filed with the Securities and Exchange Commission on February 9, 2012.

Edgar Filing: HBM BIOVENTURES CAYMAN LTD - Form SC 13G

Item 1(a).	Name of Issuer:
Item 1(b).	ChemoCentryx, Inc. Address of Issuer's Principal Executive Offices: 850 Maude Avenue  Mountain View, CA 94043
Item 2(a).	Name of Person Filing:
Item 2(b).	HBM BioVentures (Cayman) Ltd. Address of Principal Business Office or, if none, Residence: Centennial Towers, 3rd Floor  2454 West Bay Road  Grand Cayman, Cayman Islands
Item 2(c).	Citizenship:
Item 2(d).	Cayman Islands, British West Indies
Item 2(e).	Title of Class of Securities: Common Stock CUSIP Number: 16383L106
Item 3.	<b>If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:</b> Not applicable

**Item 4.**

**Ownership**

- |     |  |  |
|-----|--|--|
| (a) | Amount beneficially owned:                   |  |
|     |  | 2,637,301(1)   |
| (b) | Percent of class:                            |  |
|     |  | 7.9%(2)  |
| (c) | Number of shares as to which the person has: |  |
|     |  |  |
|     | (i)  | Sole power to vote or to direct the vote                                 |
|     |  |  |
|     | (ii)   | 2,637,301(1)<br>Shared power to vote or to direct the vote:              |
|     |  |  |
|     | (iii)  | 0<br>Sole power to dispose or to direct the disposition of:              |
|     |  |  |
|     | (iv)   | 2,637,301(1)<br>Shared power to dispose or to direct the disposition of: |
|     |  |  |
|     |  | 0  |

**Item 5.**

**Ownership of 5 Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

**Item 6.**

**Ownership of More than 5 Percent on Behalf of Another Person**

Not applicable

**Item 7.**

**Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person**

Not applicable

**Item 8.**

**Identification and Classification of Members of the Group**

Not applicable

**Item 9.**

**Notice of Dissolution of a Group**

Not applicable

---

(1) The Board of Directors of HBM BioVentures (Cayman) Ltd. has sole voting and investment power with respect to the shares held by such entity and acts by majority vote. The board of directors of HBM BioVentures (Cayman) Ltd. is comprised of John Arnold, Sophia Harris, Richard Coles, Dr. Andreas Wicki and John Urquhart, none of whom has individual voting or investment power with respect to the shares.

**Item 10.**

Not applicable

**Certification**

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 16, 2012

**HBM BIOVENTURES (CAYMAN) LTD.**

By:

/s/ John Arnold

John Arnold  
Chairman and Managing Director

**ATTENTION:**

**Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001)**